ARWR
Arrowhead Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$71.65-3.57%
Price as of Jul 20, 2026
ARWR growth
Arrowhead Pharmaceuticals, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +9.4%
- EBITDA
- -97.4%
- EBIT
- -87.2%
- EPS
- -54.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
- Revenue
- -70.0%
- EBITDA
- +12.4%
- EPS
- —
Three-year CAGR
- Revenue
- +50.5%
- EBITDA
- +129.4%
- EBIT
- +116.4%
- Net income
- +99.7%
- EPS
- +99.8%
- Free cash flow
- +126.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.